Literature DB >> 3946978

Amiodarone hepatotoxicity. A clinicopathologic study of five patients.

B Rigas, L E Rosenfeld, K W Barwick, R Enriquez, J Helzberg, W P Batsford, M E Josephson, C A Riely.   

Abstract

Five patients had amiodarone hepatotoxicity detected on routine biochemical monitoring. Symptoms attributable to hepatotoxicity were minimal or absent; reversible hepatomegaly was seen in two patients, whereas three patients had signs of nonhepatic amiodarone toxicity before or with hepatotoxicity. Serum aminotransferase levels were elevated in all patients and alkaline phosphatase levels in four; no patient had hyperbilirubinemia or prolongation of the prothrombin time. Light microscopy showed steatosis, cellular degeneration, and cellular necrosis in the biopsy samples of four patients, whereas the fifth patient's sample had a granulomatous injury pattern. Electron microscopic study of liver tissue done in two patients showed phospholipid-laden lysosomal lamellar bodies. These findings suggest that both toxic and hypersensitivity liver injury can occur in response to amiodarone. The presence of phospholipid-laden lysosomal lamellar bodies may help differentiate amiodarone hepatotoxicity from alcoholic liver disease or other causes of hepatic steatosis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3946978     DOI: 10.7326/0003-4819-104-3-348

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  15 in total

1.  Glucosylceramide and lysophosphatidylcholines as potential blood biomarkers for drug-induced hepatic phospholipidosis.

Authors:  Kosuke Saito; Keiko Maekawa; Masaki Ishikawa; Yuya Senoo; Masayo Urata; Mayumi Murayama; Noriyuki Nakatsu; Hiroshi Yamada; Yoshiro Saito
Journal:  Toxicol Sci       Date:  2014-06-30       Impact factor: 4.849

2.  Acute hepatic dysfunction following parenteral amiodarone administration.

Authors:  R N Stevenson; T H Nayani; J R Davies
Journal:  Postgrad Med J       Date:  1989-09       Impact factor: 2.401

3.  P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

Authors:  Matthew G McDonald; Nicholas T Au; Allan E Rettie
Journal:  Drug Metab Dispos       Date:  2015-08-21       Impact factor: 3.922

4.  Granular cells as a marker of early amiodarone hepatotoxicity: a pathological and analytical study.

Authors:  N A Shepherd; A M Dawson; P R Crocker; D A Levison
Journal:  J Clin Pathol       Date:  1987-04       Impact factor: 3.411

5.  Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis.

Authors:  A Nonomura; Y Mizukami; M Unoura; K Kobayashi; Y Takeda; R Takeda
Journal:  Gastroenterol Jpn       Date:  1992-08

6.  Role of vitamin-E on rat liver-amiodarone: an ultrastructural study.

Authors:  Mohamed Samir A Zaki; Refaat A Eid
Journal:  Saudi J Gastroenterol       Date:  2009-04       Impact factor: 2.485

7.  Differences in hepatic drug accumulation and enzyme induction after chronic amiodarone feeding of two rat strains: role of the hydroxylator phenotype?

Authors:  M Pirovino; U Honegger; O Müller; T Zysset; A Küpfer; M Tinel; D Pessayre
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

Review 8.  New Avenues for Treatment and Prevention of Drug-Induced Steatosis and Steatohepatitis: Much More Than Antioxidants.

Authors:  Mauro Cataldi; Vincenzo Citro; Chiara Resnati; Federica Manco; Giovanni Tarantino
Journal:  Adv Ther       Date:  2021-03-24       Impact factor: 3.845

9.  Amiodarone hepatotoxicity with absent phospholipidosis and steatosis: a case report and review of amiodarone toxicity in various organs.

Authors:  Adela Cimic; Joseph Sirintrapun
Journal:  Case Rep Pathol       Date:  2013-05-20

10.  Amiodarone-induced cirrhosis of liver: what predicts mortality?

Authors:  Nasir Hussain; Anirban Bhattacharyya; Suartcha Prueksaritanond
Journal:  ISRN Cardiol       Date:  2013-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.